Effect of Bromocriptine Mesylate as Add-On Therapy in Obese Type 2 Diabetes Mellitus Patients
Authors
Abstract:
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese type 2 diabetic patients.
similar resources
effect of bromocriptine mesylate as add-on therapy in obese type 2 diabetes mellitus patients
six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (hba1c), fasting blood sugar, postprandial blood sugar, and weight of 22 indian obese patients with type 2 diabetes mellitus with no serious adverse events. therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese typ...
full textEffect of Teneligliptin supplementation as add on therapy to Metformin in Uncontrolled type 2 diabetes mellitus
Diabetes mellitus type 2 (DM) is a long term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Metformin is first line drug for diabetes mellitus due to its excellent safety and toleralability. Teneligliptin is newly approved drug for DM and having minimal side effects. Teneligliptin can be used either as monotherapy or add on therap...
full textEffects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
INTRODUCTION Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), the biochemical markers of coronary atherosclerosis/inflammation, in patients with uncontrolled T2DM...
full textEffect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
AIMS To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period. METHODS AND RESULTS The study sample comprised 339 non-diabetic obese patients (body mass index > or = 30.0 kg/m2) aged 42-74. Patients received either bezafibrate retard 400 mg (178 patients) or placebo (161 patients) once daily. Developm...
full textLinagliptin as add-on therapy to insulin for patients with type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenien...
full textEffect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
AIMS A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. MATERIALS AND METHODS A total of 68 type 2 DM patients who were on metformin were enrolled...
full textMy Resources
Journal title
volume 5 issue 2
pages 88- 90
publication date 2013-06
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023